SABS
Undervalued by 86.3% based on the discounted cash flow analysis.
Market cap | $33.49 Million |
---|---|
Enterprise Value | $-17,170,464.00 |
Dividend Yield | $0.0 (0.0%) |
Earnings per Share | $-7.64 |
Beta | 0.12 |
Outstanding Shares | 9,225,494 |
Avg 30 Day Volume | 6,057 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | -0.79 |
---|---|
PEG | -0.42 |
Price to Sales | - |
Price to Book Ratio | 0.61 |
Enterprise Value to Revenue | -7.67 |
Enterprise Value to EBIT | 0.45 |
Enterprise Value to Net Income | 0 |
Total Debt to Enterprise | -0.34 |
Debt to Equity | 0.1 |
No data
No data
sab biotherapeutics is a clinical-stage biopharmaceutical development company using its novel immunotherapy platform to produce life-saving therapies.